Correction: Update: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

-- (Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)

BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.

Analysts polled by FactSet expected a loss of 1.27 euros.

Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.

Analysts surveyed by FactSet expected 164.6 million euros.

For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts expect 2.22 billion euros.

The company said it plans to exit operations at manufacturing sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac's sites, affecting up to about 1,860 positions. The moves are expected to be completed by 2027 and deliver about 500 million euros in annual cost savings by 2029.

BioNTech shares were down 2.4% in Tuesday trading.

Price: $96.80, Change: $-2.55, Percent Change: -2.57%

Piper Sandler 将 Henry Schein 的目标股价从 99 美元下调至 91 美元。

根据FactSet调查的分析师报告，亨利·谢恩公司（Henry Schein，股票代码：HSIC）的平均评级为“增持”，平均目标价为90.21美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $74.05, Change: $+2.03, Percent Change: +2.82%

$HSIC

汇丰银行将卡特彼勒目标股价从850美元上调至1100美元

根据FactSet调查的分析师报告，卡特彼勒（CAT）的平均评级为“增持”，平均目标价为893.22美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $899.58, Change: $+24.80, Percent Change: +2.83%

$CAT

Piper Sandler 将 KKR 的目标股价从 117 美元上调至 125 美元。

根据FactSet调查的分析师数据，KKR (KKR) 的平均评级为“买入”，平均目标价为124.61美元。（报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）Price: $101.18, Change: $-2.15, Percent Change: -2.08%

$KKR

相关文章

Piper Sandler 将 Henry Schein 的目标股价从 99 美元下调至 91 美元。

汇丰银行将卡特彼勒目标股价从850美元上调至1100美元

Piper Sandler 将 KKR 的目标股价从 117 美元上调至 125 美元。